Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection

被引：6

作者：

Tsai, Yu-Fen ^{[1
,2
]}

Liu, Yi-Chang ^{[3
,4
]}

Yang, Ching-, I ^{[3
,5
]}

Chuang, Tzer-Ming ^{[3
]}

Ke, Ya-Lun ^{[3
]}

Yeh, Tsung-Jang ^{[3
]}

Gau, Yuh-Ching ^{[3
]}

Du, Jeng-Shiun ^{[3
]}

Wang, Hui-Ching ^{[3
,4
]}

Cho, Shih-Feng ^{[3
,4
]}

Hsu, Chin-Mu ^{[3
]}

Wu, Pey-Fang ^{[6
]}

Huang, Ching-, I ^{[4
,6
]}

Huang, Chung-Feng ^{[4
,6
]}

Yu, Ming-Lung ^{[4
,6
]}

Dai, Chia-Yen ^{[4
,6
]}

Hsiao, Hui-Hua ^{[3
,4
,7
,8
]}

机构：

[1] E Da Canc Hosp, Dept Hematol & Oncol, Kaohsiung 824, Taiwan

[2] I Shou Univ, Coll Med, Sch Chinese Med Post Baccalaureate, Kaohsiung 824, Taiwan

[3] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Kaohsiung 807, Taiwan

[4] Kaohsiung Med Univ, Fac Med, Kaohsiung 807, Taiwan

[5] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Specialist Nurse & Surg Nurse Practitioner Off, Kaohsiung 807, Taiwan

[6] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Hepatobiliary Ward, Kaohsiung 807, Taiwan

[7] Kaohsiung Med Univ, Ctr Liquid Biopsy, Kaohsiung 807, Taiwan

[8] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Canc Ctr, Kaohsiung 807, Taiwan

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 09期

关键词：

hepatitis C virus; diffuse large B-cell lymphoma; survival; fibrosis; performance status; liver toxicity; NON-HODGKIN-LYMPHOMA; VIRUS-POSITIVE PATIENTS; TAIWAN; FIBROSIS; RISK; PREVALENCE; RITUXIMAB; TOXICITY; THERAPY; MODEL;

D O I：

10.3390/jpm11090844

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Background: Hepatitis C virus (HCV) in diffuse large B-cell lymphoma (DLBCL) is associated with a higher prevalence and distinctive clinical characteristics and outcomes. Methods: A retrospective analysis of adult DLBCL patients from 2011 to 2015 was studied. Results: A total of 206 adult DLBCL were enrolled with 22 (10.7%) HCV-positive patients. Compared to HCV-negative patients, the HCV-positive group had a poor performance status (p = 0.011), lower platelet count (p = 0.029), and higher spleen and liver involvement incidences (liver involvement, p = 0.027, spleen involvement, p = 0.026), and they received fewer cycles of chemotherapy significantly due to morbidity and mortality (p = 0.048). Overall survival was shorter in HCV-positive DLBCL (25.3 months in HCV-positive vs. not reached (NR), p = 0.049). With multivariate analysis, poor performance status (p < 0.001), advanced stage (p < 0.001), less chemotherapy cycles (p < 0.001), and the presence of liver toxicity (p = 0.001) contributed to poor OS in DLBCL. Among HCV-positive DLBCL, the severity of liver fibrosis was the main risk factor related to death. Conclusion: Inferior survival of HCV-positive DLBCL was observed and associated with poor performance status, higher numbers of complications, and intolerance of treatment, leading to fewer therapy. Therefore, anti-HCV therapy, such as direct-acting antiviral agents, might benefit these patients in the future.

引用

页数：13

共 41 条

[1] Hepatitis C Virus Infection and Antiviral Treatment in Marginal Zone Lymphomas [J].